EMCDDA Home
  • EN
Search

Report on the risk assessment of 3,4-dichloro-N-{[1-(dimethylamino)cyclohexyl]methyl}benzamide (AH-7921) in the framework of the Council Decision on new psychoactive substances

EMCDDA, Lisbon, May 2014

Publication type:

Risk assessments

Issue:

13

Summary:

This report presents the data and findings of the risk assessment on the new psychoactive substance, 3,4-dichloro-N-{[1-(dimethylamino)cyclohexyl]methyl}benzamide (AH-7921), that was conducted by the Scientific Committee of the EMCDDA. Concerns over this synthetic opioid in the European Union led to an assessment of the health and social risks posed by the substance in April 2014.

Download as pdf (320Kb):

English (en)

Table of contents

  • EMCDDA actions on monitoring and responding to new drugs
  • EMCDDA–Europol Joint Report on AH-7921: a summary
  • Risk Assessment Report of a new psychoactive substance: AH-7921
  • Annex 1: Technical report on AH-7921
  • Council Implementing Decision of 25 September 2014 on subjecting 25I-NBOMe, AH-7921, MDPV and methoxetamine to control measures
  • Participants of the risk assessment meeting

Pages:

23

Price:

free

ISBN/ISSN:

978-92-9168-746-6

DOI:

10.2810/5691

Catalogue number:

TDAK14002ENN

About the EMCDDA

The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is the reference point on drugs and drug addiction information in Europe. Inaugurated in Lisbon in 1995, it is one of the EU's decentralised agencies. Read more >>

Contact us

EMCDDA
Praça Europa 1, Cais do Sodré
1249-289 Lisbon
Portugal
Tel. (351) 211 21 02 00

More contact options >>

Page last updated: Wednesday, 08 October 2014